.png){kind=icon}
.png){kind=icon}
Return
Clinical and Immunological Characteristics of Bullous Pemphigoid Patients With Psoriasis Comorbidity: A Retrospective Study
.png){kind=icon}
PRE
AI
L
L
H
Y
K
S
Z
T
S
DOI：10.1111/exd.70306.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Despite the recognized association between bullous pemphigoid (BP) and psoriasis, the clinical and immunological profiles, and inflammation patterns of coexistence remain undefined. We therefore conducted a retrospective cohort study of 140 BP patients without psoriasis (BP alone group) and 24 BP patients with comorbid psoriasis (BP-PsO group) to characterise these features. Average age of BP onset was significantly lower in the BP-PsO group, compared with the BP alone group (median [IQR]: 67.00 [58.00–75.75] years vs. 75.00 [64.00–82.00] years) (p = 0.021). In the BP-PsO group, 21 patients (87.5%) had coexisting active psoriatic plaques and BP lesions. The overall disease activity of BP was comparable between the BP-PsO and BP alone groups, both showing typical BP immunological features. Serum IL-17A level was significantly elevated in the BP-PsO group (median [IQR]: 18.29 [10.39–43.50] pg/mL), compared with the BP alone group (median [IQR]: 10.36 [9.16–12.11] pg/mL) and psoriasis alone groups (median [IQR]: 11.65 [10.10–12.78] pg/mL), and correlated with disease activity. Flow cytometry confirmed enhanced IL-17A response in peripheral blood mononuclear cells from the BP-PsO group, with an elevated proportion of CD4+ IL-17A+ cells and IL-17A+ T follicular helper cells versus corresponding controls. IL-13 was comparably elevated in both the BP-PsO and BP alone groups, relative to psoriasis alone group and healthy controls. In a representative case, inhibition of IL-17A led to concurrent remission of both diseases. BP with psoriasis shares foundational features with idiopathic BP, but represents a distinct clinical entity characterised by a predominant IL-17A signature, highlighting its potential as a therapeutic target.
Keywords:
bullous pemphigoid
comorbidity
IL-17A
psoriasis
type-2 inflammation
Journal
IF:
3.1
Papers:
4.9K
Citations:
1.0W
Organization
Cited Papers